Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib with Chemoradiotherapy in HNSCC
NCT02107235Phase 1Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- Jan 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rigosertib in head and neck squamous cell carcinoma (HNSCC), sponsored by Traws Pharma, Inc. Primary endpoint: Dose Limiting Toxicities at 12 weeks. Started Jan 2014; status: completed.
02
Drugs
rigosertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02107235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107235.